Cothera Bioscience — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Cothera Bioscience is a private, clinical-stage oncology biotech leveraging a platform centered on synthetic lethality and protein degradation to drug historically challenging targets like Myc. Its pipeline features two lead assets: sepantronium bromide (PC-002), a first-in-class DUB inhibitor in Phase 2 for Myc-driven lymphomas, and zotiraciclib (ZTR), an oral CDK9/PIM inhibitor with Fast Track designation for IDH-mutant high-grade glioma. Founded by veterans from Crown Bioscience and Silicon Valley, the company is pre-revenue, advancing its programs through clinical trials and strategic collaborations, including with the National Cancer Institute.

Oncology

Technology Platform

A clinically validated translational platform exploiting synthetic lethality and protein degradation (via DUB inhibition) pathways to target undruggable oncology targets.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
Sepantronium Bromide	High-grade B-cell Lymphoma	Phase 2

Opportunities

Fast Track designation for zotiraciclib accelerates its development path in IDH-mutant glioma, a high-need area.

The company's platform offers a validated approach to target Myc, a major oncogene, opening a broad pipeline potential across multiple cancer types.

Collaboration with the NCI provides non-dilutive funding and expert clinical trial execution.

Risk Factors

High clinical development risk as both lead assets are in Phase 2, where many oncology candidates fail.

Intense competition in protein degradation and kinase inhibitor spaces from larger, better-funded companies.

Financial risk as a pre-revenue private company dependent on fundraising in a volatile capital market.

Competitive Landscape

Cothera competes in the rapidly evolving fields of targeted protein degradation (TPD) and synthetic lethality. In TPD, it faces competition from companies like Nurix Therapeutics and Kymera Therapeutics targeting various E3 ligases, while Cothera's DUB inhibitor approach is distinct. In IDH-mutant glioma, it competes with approved agents like vorasidenib (servios) and other brain-penetrant inhibitors. Its niche is combining these modalities for specific genetic vulnerabilities.

More companies in Small Molecule Drugs →More companies in United States →